Bruce E. Sands - Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai

基本信息

浏览量：179

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 78 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

OP05 Primary Efficacy and Safety of Mirikizumab in Moderate to Severe Crohn’s Disease: Results of the Treat-Through VIVID 1 Study

Marc Ferrante,Silvio Danese, M Chen,Geert DʼHaens,Subrata Ghosh,Tadakazu Hisamatsu,Vipul Jairath,Jarosław Kierkuś,Laurent Peyrin‐Biroulet,B Siegmund, Sonja M. Bragg,Wallace Crandall,Theresa Hunter Gibble, Lin Zhang, M. C. A. Lopes,Nathan Morris,Hilde Carlier,Bruce E. Sands

Journal of Crohn's and colitisno. Supplement_1 (2024): i7-i9

引用0浏览0引用

Mucosal and Transmural Healing and Long-term Outcomes in Crohn's Disease

Bruce E Sands,Silvio Danese,J Casey Chapman,Khushboo Gurjar,Stacy Grieve,Deepika Thakur,Jenny Griffith, Namita Joshi,Kristina Kligys,Axel Dignass

Inflammatory bowel diseases (2024)

引用0浏览0WOS引用

Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results from the LUCENT-3 Open-Label Extension Study

Bruce E Sands, Geert D'Haens, David B Clemow,Peter M Irving, Jordan T Johns,Theresa Hunter Gibble,Maria T Abreu,Scott D Lee,Tadakazu Hisamatsu,Taku Kobayashi,Marla C Dubinsky,Severine Vermeire,Corey A Siegel, Laurent Peyrin-Biroulet, Richard E Moses, Joe Milata,Remo Panaccione,Axel Dignass

Inflammatory bowel diseases（2024）

引用0浏览0WOS引用

Analysis of Tofacitinib Safety in Ulcerative Colitis from the Completed Global Clinical Developmental Program Up to 9.2 Years of Drug Exposure

Julian Panes,Geert R. D'Haens,Bruce E. Sands,Siew C. Ng,Nervin Lawendy,Nicole Kulisek,Xiang Guo,Joseph Wu,Ivana Vranic,Remo Panaccione,Severine Vermeire

UNITED EUROPEAN GASTROENTEROLOGY JOURNALno. 6 (2024): 793-801

引用0浏览0WOS引用

Impact of Biologics and Small-Molecule Agents on Postoperative Complications in IBD: A Systematic Review

Kate E. Lee, J. Alexander Sizemore,Grace Kim,Bo Shen,Bruce E. Sands

DISEASES OF THE COLON & RECTUM (2024): S11-S25

引用0浏览0WOS引用

S1453 Disease Characteristics Associated with Bowel Urgency in Crohn’s Disease: Results from the Phase 3 VIVID-1 Trial

Geert R. D'Haens,Bruce E. Sands,Vipul Jairath,Simon Travis, Maria Chaparro, Laurent Peyrin-Biroulet,Minhu Chen,Marla C. Dubinsky,Marc Ferrante,Stefan Schreiber, Kim McGinnis, Aisha Vadhariya,Guanglei Yu,Marijana Protic, Richard Moses,Subrata Ghosh

American Journal of Gastroenterologyno. 10S (2024)

引用0浏览0引用

S1448 Impact of Prior Biologic Exposure on the Durability of Ozanimod over 5 Years of Continuous Treatment in Patients with Ulcerative Colitis: an Interim Analysis of the True North Open-Label Extension Study

Bruce E. Sands,Caterina Oneto,Zachary A. Borman,Gaurav Syal,Ryan C. Ungaro,Marc Ferrante, James O. Lindsay,Irina Blumenstein, Zhaohui Liu, Dimpy Mehra,Anjali Jain, Geert R. D'Haens

American Journal of Gastroenterology（2024）

引用0浏览0引用

Clinical Trial Design Considerations for Hospitalised Patients with Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT-UC Consortium

Parambir S Dulai, Lauren Balmert Bonner,Charlotte Sadler,Laura E Raffals, Gursimran Kochhar,Peter Lindholm,Jay C Buckey, Gary N Toups, Libeth Rosas, Neeraj Narula,Vipul Jairath, Sailish Honap,Laurent Peyrin-Biroulet,Bruce E Sands,Stephen B Hanauer, Denise M Scholtens,Corey A Siegel, HBOT‐UC Consortium Investigators

Alimentary pharmacology & therapeutics (2024)

引用0浏览0WOS引用

Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study

Waqqas Afif,Ramesh P. Arasaradnam,Maria T. Abreu,Silvio Danese,William J. Sandborn,Ye Miao,Hongyan Zhang,Remo Panaccione,Tadakazu Hisamatsu,Ellen J. Scherl,Rupert W. Leong,David S. Rowbotham,Laurent Peyrin-Biroulet,Bruce E. Sands,Colleen Marano

AMERICAN JOURNAL OF GASTROENTEROLOGYno. 5 (2024): 910-921

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn